The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Addition of darbepoetin alfa to sequential high-dose VIP chemotherapy for patients with advanced metastatic germ cell cancer.
Joerg Thomas Hartmann
No relevant relationships to disclose
Bernd Metzner
No relevant relationships to disclose
Claudia Binder
No relevant relationships to disclose
Hans-Guenther Mergenthaler
No relevant relationships to disclose
Oliver Rick
No relevant relationships to disclose
Herbert G Sayer
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Joerg Beyer
No relevant relationships to disclose
Anja Lorch
No relevant relationships to disclose
Wolfgang E. Berdel
No relevant relationships to disclose
Norbert Frickhofen
No relevant relationships to disclose
Carsten Bokemeyer
No relevant relationships to disclose
Jan Schleicher
No relevant relationships to disclose
Thomas C. Gauler
No relevant relationships to disclose